Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Inclusion Criteria: * Ability and willingness to provide informed consent * HIV-1 infection prior to entry * Receiving suppressive ART therapy for a minimum of 24 consecutive months prior to screening with no interruption of therapy (same ART regimen for at least 12 weeks prior to screening) * Documented suppressed HIV-1 RNA (plasma HIV-1 RNA values \<50 copies/ml) * CD4 T cell count ≥ 400 cells/mm3 * Negative Hepatitis B surface antigen (HBsAg) or Negative HBV DNA PCR * Negative anti-Hepatitis C virus antibodies (anti-HCV) or negative HCV PCR if anti-HCV antibodies are positive * Negative TB Test (if positive, completed a recommended treatment course for latent TB) * Vaccinated for pneumococcal disease within last 5 years * No clinically significant eye disease * No evidence of clinical coronary heart disease * Not pregnant, planning to become pregnant, or breastfeeding * Willingness to continue to use contraceptives for 90 days after completing treatment * If male, willingness to use a condom during intercourse while taking panobinostat and total of 80 hours after stopping treatment * Not pregnant, planning to become pregnant, or breastfeeding * No evidence of coronary heart disease Exclusion Criteria: * HIV-1 RNA \> 50 copies/mL within 24 months of screening * Severe psychiatric disease, chronic liver disease, past or current evidence of immunologically mediated disease * Severe retinopathy due to diabetes, hypertension, cytomegalovirus or macular degeneration * Evidence of coronary heart disease * History of active thyroid disease requiring medication * Breastfeeding * Presence of a bacterial, fungal, viral or protozoal infection requiring systemic anti-infective therapy * Uncontrolled seizure disorders * History or other evidence of severe illness or other conditions * History of malignancy of any organ system within the past 5 years * Female participants who are pregnant or nursing * History of solid organ transplantation with an existing functional graft * Use of any immunomodulatory agents within 30 days prior to study enrollment or planned use during the trial * Active drug or alcohol use or dependence * Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant in case of participation in the study * Use of HIV protease inhibitor or other strong or moderately strong CYP3A4 inhibitors * History of anaphylaxis, allergy or serious adverse reactions to Interferon-alpha2a/Interferon-alpha2b or panobinostat * Has taken: interleukins, systemic interferons or systemic chemotherapy